Genmab A/S (GMAB) financials
- Dec 2025
Price
$38.5 +4.05% · +$1.5
Performance +16.1% 1Y
1Y: $33.17 on 17 Oct 2025 → $38.5. High $38.5 (19 Oct 2026), low $23.85 (2 Jun 2026).
- Previous close
- $37
- 52-week range
- $23.85 – $38.5
- One year
- +26.06%
Overview
- Symbol
- GMAB
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Exchange
- US
- Currency
- USD
Financials
What the filings say
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total liabilities | 69 | 165 | 333 | 370 | 2,837 | 545 | 1,277 | 7,026 |
| Fixed assets | 25 | 36 | 75 | 95 | 799 | 142 | 137 | 153 |
| Total assets | 1,297 | 2,277 | 3,487 | 3,737 | 30,119 | 5,232 | 6,414 | 12,873 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 156 | 199 | 1,061 | 339 | 3,912 | 1,071 | 1,126 | 1,186 |
| Cash from investing | -273 | -298 | -388 | -146 | -2,761 | -185 | -1,447 | -5,643 |
| Cash from financing | -11 | 550 | 12 | -64 | -789 | -89 | -566 | 4,789 |
| Capital expenditure | -11 | -12 | -51 | -38 | -317 | -53 | -27 | -37 |
| Free cash flow | 145 | 187 | 1,010 | 301 | 3,595 | 1,018 | 1,099 | 1,149 |
Insider filings
No filings in the last 12 months.
No officer, director or 10% owner of GMAB filed a Form 4 in this window. That is a statement about filings, not about ownership — see the note below.
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for GENMAB A/S
Free account. Everything above stays public.
Write why you follow GENMAB A/S and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading